In this online, self-learning activity:
Cancer of the liver is one of the leading causes of cancer-related deaths and one of the more common types of cancer worldwide, with an incidence of over 41,000 in the U.S. and an annual mortality rate of over 29,000 new cases each year. Of all the primary liver cancers, hepatocellular carcinoma (HCC) is the most common form, representing 80%, and its incidence has risen threefold in the U.S. over the past 40 years. HCC is most often diagnosed in late stages of disease and carries a grave prognosis with a five-year survival rate of three percent in patients with metastases, suggesting opportunity for improvement and potential gaps in care.
HCPs including: medical oncologists, gastroenterologists, and hepatologists; physician assistants, nurse practitioners, and pharmacists who practice in oncology; and any other healthcare professionals with an interest in or who clinically encounter patients with advanced or unresectable HCC.
Commercial Support Disclosure: This program is supported by an educational grant from Merck.
This activity is free of charge.
Release Date: February 03, 2024 -- Expiration Date: February 03, 2025
Faculty: Tanios Bekaii‐Saab, MD
and other recent society meetings
By the end of the session the participant will be able to:
ACCME Activity #202614064
ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review by ScientiaCME.
Disclosure of Faculty: Tanios S. Bekaii‐Saab, MD, Professor of Medicine, Mayo Clinic Collegeof Medicine and Science, has received financial compensation from Stemline, AbbVie, Blueprint Medicines , Boehringer Ingelheim, Janssen, Daiichi Sankyo, Natera, TreosBio, Celularity, Caladrius Biosciences, Exact Science, Sobi, Beigene, Kanaph, Astra Zeneca, Deciphera, Zai Labs, Exelixis, MJH Life Sciences, Aptitude Health, Illumina, Foundation Medicine, Sanofi, Glaxo SmithKlin, Imugene, Immuneering, Xilis, Replimune, Artiva and Sun Biopharma for consulting and/or advisory board activities.
Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.
Faculty WILL NOT discuss off-label uses.
All relevant financial relationships have been mitigated.
ScientiaCME adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Commercial Support Disclosure: This program is supported by an educational grant from Merck.
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.
Advanced systemic mastocytosis: from recognition to treatment
Taking the ‘pep’ out of H. pylori infection: updates in practice and treatment optimization
Acute hepatic porphyria: optimizing pharmacotherapeutic management strategies
Contemporary treatment approaches in the management of graft-versus-host disease (GVHD)